Fox Run Management, L.L.C. Intercept Pharmaceuticals, Inc. Transaction History

Fox Run Management, L.L.C.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	BUY	$12.53 - $21.71 $334,212 - $579,070	26,673 New	26,673 $358,000
Q2 2022 Aug 12, 2022	BUY	$11.23 - $19.59 $79,923 - $139,422	7,117 Added 173.63%	11,216 $155,000
Q2 2019 Jul 17, 2019	BUY	$77.77 - $120.68 $318,779 - $494,667	4,099 New	4,099 $326,000
Q1 2018 Apr 17, 2018	SELL	$52.72 - $67.25 $1.04 Million - $1.33 Million	-19,786 Closed	0 $0
Q4 2017 Jan 18, 2018	BUY	$58.2 - $72.76 $633,565 - $792,065	10,886 Added 122.31%	19,786 $1.16 Million
Q3 2017 Oct 23, 2017	BUY	$57.01 - $118.75 $507,389 - $1.06 Million	8,900	8,900 $517,000

1.04M

30K

5.9K

Ticker ICPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,127,400
Description
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination wit...

Get notified when there are updates to the investment portfolio of Fox Run Management, L.L.C., based on Form 13F filings with the SEC.

Stay updated on Fox Run Management, L.L.C. with notifications on news.